VolitionRx stock faces Q3 focus as revenue rises 157%

VolitionRx reported third-quarter 2026 results on Thursday, November 12, showing revenue of approximately 1.6 million US dollars, up 157 percent from the year-earlier quarter. The company attributed the increase primarily to recognition of deferred revenue, according to PR Newswire via Yahoo Finance.

Losses narrow as revenue increases

Operating expenses fell 14 percent from the prior-year period, helped by Volition's cost-reduction program and a 28 percent reduction in headcount. The operating loss narrowed to approximately 3.3 million US dollars from 5.1 million US dollars, while the net loss declined to about 3.8 million US dollars from 5.4 million US dollars. The net loss included 0.4 million US dollars in non-cash convertible-note charges.

Cash and cash equivalents stood at approximately 2.4 million US dollars on September 30, compared with 1.1 million US dollars at the end of 2025. Volition said it received about 5.2 million US dollars in net proceeds from its at-the-market facility during the quarter and prepaid the outstanding balance of a 7.5 million US dollar convertible note.

Commercial milestones remain central

Management said Volition is advancing a French reimbursement submission for Nu.Q Lung Cancer and currently expects to file it during the fourth quarter. The company also cited the DETECSEPS program in France, which is evaluating its Nu.Q NETs assay for early sepsis detection, and an October letter of intent with Missionpharma for a lateral-flow test targeting neonatal sepsis triage and prognostication.

Volition said it is in licensing discussions for Capture-Seq technology aimed at multi-cancer early detection and minimal residual disease testing. It also expects publication of a feline lymphoma study this quarter; a peer-reviewed publication demonstrating clinical utility is required for a potential 5 million US dollar milestone payment.

Specialized diagnostics platform

VolitionRx is a multinational epigenetics company developing and commercializing blood tests for earlier detection and monitoring of cancers and diseases associated with NETosis, including sepsis. Its research activities are centered in Belgium, with additional operations in the United States, London and Singapore.

The company follows a partnership-led model, working with diagnostic groups including Sysmex and Werfen while developing its own Nu.Q and Capture-Seq platforms. This gives Volition a specialized position in blood-based diagnostics, but also leaves commercialization dependent on clinical validation, reimbursement and licensing progress.

In the broader market, investors can follow developments through the S&P 500 market environment.

More news and analyses on VolitionRx stock.